

**In the Claims:**

1. (Canceled).

2. (Canceled).

3. (Canceled).

4. (Amended) At least one mutant IL-13 MUT-IL-13

polypeptide, comprising all of the contiguous amino acids of SEQ ID NO:1, or with at least one substitution mutant protein thereof selected from at least one of Gln130 or Asn130 and at least one substitution mutant protein thereof selected from at least one of Ile48, Val48, Gln90, Glu90, Leu95, Ile95, Leu96, Ile96, Leu99, Ile99, Phe103, or Tyr103.

5. (Canceled).

6. (Canceled).

7. (Canceled).

8. (Canceled).

9. (Canceled).

10. (Canceled).

11. (Canceled).

12. (Canceled).

13. (Amended) A composition comprising at least one mutant IL-13 polypeptide according to claim 4-12, wherein said composition further comprises at least one pharmaceutically acceptable carrier or diluent.

14-24. (Canceled).